06
Jan
Glenmark Pharmaceuticals Limited has launched a fixed-dose combination (FDC) of its novel, patent protected and globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed-dose and must be taken twice daily. Glenmark has launched the same under two brand names Remo V and Remozen V. Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin fixed dose…